*In the 12-week trial, there was 1 joint effusion reported in the EUFLEXXA group (n=160) vs 13 joint effusions in the Synvisc® (hylan G-F 20) group (n=161).1
EUFLEXXA (1% sodium hyaluronate) is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpharmacologic therapy and simple analgesics (e.g., acetaminophen).
IMPORTANT SAFETY INFORMATION
EUFLEXXA is contraindicated in patients who have a known hypersensitivity to hyaluronate preparations or who have knee joint infections, infections, or skin disease in the area of the injection site.Click to Expand
EUFLEXXA should not be administered through a needle previously used with medical solutions containing benzalkonium chloride.
Do not use skin disinfectants for skin preparation that contain quaternary ammonium salts.
Do not inject intravascularly due to potential for systemic adverse events.
The safety and effectiveness of injection in conjunction with other intra-articular injectables, or into joints other than the knee have not been studied. Remove any joint effusion prior to injecting. Transient pain or swelling of the injected joint may occur after intra-articular injection with EUFLEXXA.
The most common adverse events related to EUFLEXXA injections reported in 12- and 26-week clinical studies were arthralgia, back pain, pain in extremity, musculoskeletal pain, and joint swelling. In an open-label extension of the 26-week clinical study with repeat series of injections, the most common adverse events related to EUFLEXXA at Week 52 were arthralgia and joint swelling.
This website is intended only for US residents.
EUFLEXXA® is a registered trademark of Ferring B.V.
All other trademarks are property of their respective owners.